Other

Notes and other receivables

Edwards Lifesciences Notes and other receivables decreased by 21.0% to $137.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.2%, from $147.80M to $137.20M. Over 2 years (FY 2023 to FY 2025), Notes and other receivables shows an upward trend with a 5.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_other_receivable_after_allowance_for_credit_loss_n_f66c21

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$155.10M$159.50M$172.30M$132.90M$129.30M$147.80M$205.60M$227.30M$173.70M$137.20M
QoQ Change—+2.8%+8.0%-22.9%-2.7%+14.3%+39.1%+10.6%-23.6%-21.0%
YoY Change————-16.6%-7.3%+19.3%+71.0%+34.3%-7.2%
Range$129.30M – $227.30M
CAGR-5.3%
Avg YoY Growth+15.6%
Median YoY Growth+6.1%
Current Streak2 quarters decline

Frequently Asked Questions

What is Edwards Lifesciences's notes and other receivables?
Edwards Lifesciences (EW) reported notes and other receivables of $137.20M in Q1 2026.
How has Edwards Lifesciences's notes and other receivables changed year-over-year?
Edwards Lifesciences's notes and other receivables decreased by 7.2% year-over-year, from $147.80M to $137.20M.
What is the long-term trend for Edwards Lifesciences's notes and other receivables?
Over 2 years (2023 to 2025), Edwards Lifesciences's notes and other receivables has grown at a 5.8% compound annual growth rate (CAGR), from $155.10M to $173.70M.